| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JCEM.80.10.7559875 |
| P698 | PubMed publication ID | 7559875 |
| P2093 | author name string | D F Heitjan | |
| R J Santen | |||
| S J Santner | |||
| S Masamura | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2918-2925 | |
| P577 | publication date | 1995-10-01 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells | |
| P478 | volume | 80 |
| Q30355029 | A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. |
| Q34119065 | A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions |
| Q58786580 | A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells |
| Q47825566 | A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. |
| Q34315889 | Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations |
| Q30440238 | Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells |
| Q24803446 | Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs) |
| Q28344327 | Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer |
| Q35176411 | Altered radiation responses of breast cancer cells resistant to hormonal therapy |
| Q36946008 | Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved |
| Q34661852 | Aromatase inhibitors and inactivators for breast cancer therapy |
| Q43201073 | Aromatase inhibitors in advanced breast cancer: there are efficacy differences |
| Q28344270 | Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes |
| Q42381433 | Avoiding the bad and enhancing the good of soy supplements in breast cancer |
| Q30413295 | Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. |
| Q36348573 | Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer |
| Q36678693 | Cancer and fertility preservation: fertility preservation in breast cancer patients |
| Q35170042 | Clinical pharmacokinetics of aromatase inhibitors and inactivators |
| Q35233126 | Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer |
| Q30440243 | Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells |
| Q35914377 | Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth |
| Q36618242 | Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. |
| Q34658267 | Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy |
| Q30360376 | Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms |
| Q34944679 | Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents |
| Q36279700 | Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer |
| Q37340411 | Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure |
| Q34095945 | Endocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine? |
| Q24796233 | Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens |
| Q24813627 | Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q24802521 | Estrogen as therapy for breast cancer |
| Q39022052 | Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. |
| Q37182310 | Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study |
| Q33583914 | Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway |
| Q36026429 | Femara and the future: tailoring treatment and combination therapies with Femara |
| Q55267752 | Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells. |
| Q35000307 | Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. |
| Q34687037 | Identifying genes important for spermatogonial stem cell self-renewal and survival |
| Q46685190 | Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye. |
| Q33780210 | Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling |
| Q33993658 | Is there a growing role for endocrine therapy in the treatment of breast cancer? |
| Q64884689 | KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. |
| Q36138483 | Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy |
| Q33656026 | Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer. |
| Q30441321 | Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells |
| Q37633691 | Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation |
| Q36589865 | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. |
| Q36517144 | Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations |
| Q37751530 | Molecular basis for therapy resistance |
| Q35168124 | New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane |
| Q37401534 | Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors |
| Q30456637 | Occult breast tumor reservoir: biological properties and clinical significance |
| Q45788419 | Oestrogen is bad for patients with breast cancer? |
| Q36450456 | Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer |
| Q33847525 | Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer |
| Q64906586 | Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells. |
| Q95801843 | RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer |
| Q36105793 | Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic |
| Q92433417 | Successful ethinylestradiol therapy for a metastatic breast cancer patient with heavily pre-treated with endocrine therapies |
| Q35107727 | Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death |
| Q36707956 | The Role of Steroid Sulfatase as a Prognostic Factor in Patients with Endometrial Cancer |
| Q33723383 | The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells |
| Q37308154 | The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance |
| Q35827822 | The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer |
| Q34592879 | The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum |
| Q30419888 | Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival |
Search more.